Browse CIITA

Summary
SymbolCIITA
Nameclass II, major histocompatibility complex, transactivator
Aliases NLRA; NLR family, acid domain containing; nucleotide-binding oligomerization domain, leucine rich repeat and ......
Chromosomal Location16p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Nucleus, PML body Note=Recruited to PML body by PML.
Domain PF13516 Leucine Rich repeat
Function

Essential for transcriptional activity of the HLA class II promoter; activation is via the proximal promoter. No DNA binding of in vitro translated CIITA was detected. May act in a coactivator-like fashion through protein-protein interactions by contacting factors binding to the proximal MHC class II promoter, to elements of the transcription machinery, or both. Alternatively it may activate HLA class II transcription by modifying proteins that bind to the MHC class II promoter. Also mediates enhanced MHC class I transcription; the promoter element requirements for CIITA-mediated transcription are distinct from those of constitutive MHC class I transcription, and CIITA can functionally replace TAF1 at these genes. Exhibits intrinsic GTP-stimulated acetyltransferase activity. Exhibits serine/threonine protein kinase activity: can phosphorylate the TFIID component TAF7, the RAP74 subunit of the general transcription factor TFIIF, histone H2B at 'Ser-37' and other histones (in vitro).

> Gene Ontology
 
Biological Process GO:0010712 regulation of collagen metabolic process
GO:0010713 negative regulation of collagen metabolic process
GO:0032963 collagen metabolic process
GO:0032964 collagen biosynthetic process
GO:0032965 regulation of collagen biosynthetic process
GO:0032966 negative regulation of collagen biosynthetic process
GO:0034341 response to interferon-gamma
GO:0044236 multicellular organism metabolic process
GO:0044246 regulation of multicellular organismal metabolic process
GO:0044252 negative regulation of multicellular organismal metabolic process
GO:0044259 multicellular organismal macromolecule metabolic process
GO:0045341 MHC class I biosynthetic process
GO:0045342 MHC class II biosynthetic process
GO:0045343 regulation of MHC class I biosynthetic process
GO:0045345 positive regulation of MHC class I biosynthetic process
GO:0045346 regulation of MHC class II biosynthetic process
GO:0045348 positive regulation of MHC class II biosynthetic process
GO:0046677 response to antibiotic
GO:0060333 interferon-gamma-mediated signaling pathway
GO:0071346 cellular response to interferon-gamma
Molecular Function GO:0003713 transcription coactivator activity
GO:0005525 GTP binding
GO:0008022 protein C-terminus binding
GO:0008134 transcription factor binding
GO:0016746 transferase activity, transferring acyl groups
GO:0019001 guanyl nucleotide binding
GO:0032561 guanyl ribonucleotide binding
GO:0033613 activating transcription factor binding
Cellular Component GO:0016604 nuclear body
GO:0016605 PML body
> KEGG and Reactome Pathway
 
KEGG hsa04612 Antigen processing and presentation
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-913531: Interferon Signaling
R-HSA-877300: Interferon gamma signaling
Summary
SymbolCIITA
Nameclass II, major histocompatibility complex, transactivator
Aliases NLRA; NLR family, acid domain containing; nucleotide-binding oligomerization domain, leucine rich repeat and ......
Chromosomal Location16p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CIITA and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CIITA and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
16424052Breast carcinomaPromote immunity (T cell function); essential for immunotherapyTumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain. To determine if Ii expression affects presentation of MHC class II-restricted endogenously synthesized tumor antigens in human tumor cells, HLA-DR-MCF10 breast cancer cells were transduced with the CIITA, CD80 costimulatory molecule gene, and with or without small interfering RNAs (siRNA) specific for Ii.
Summary
SymbolCIITA
Nameclass II, major histocompatibility complex, transactivator
Aliases NLRA; NLR family, acid domain containing; nucleotide-binding oligomerization domain, leucine rich repeat and ......
Chromosomal Location16p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CIITA in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCIITA
Nameclass II, major histocompatibility complex, transactivator
Aliases NLRA; NLR family, acid domain containing; nucleotide-binding oligomerization domain, leucine rich repeat and ......
Chromosomal Location16p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CIITA in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.4850.365
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.6270.617
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3830.692
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.6390.175
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.630.801
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.6610.847
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.0230.054
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.4120.226
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.5360.694
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.5960.292
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.6430.454
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2080.275
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CIITA in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.907.90.26
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCIITA
Nameclass II, major histocompatibility complex, transactivator
Aliases NLRA; NLR family, acid domain containing; nucleotide-binding oligomerization domain, leucine rich repeat and ......
Chromosomal Location16p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CIITA. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCIITA
Nameclass II, major histocompatibility complex, transactivator
Aliases NLRA; NLR family, acid domain containing; nucleotide-binding oligomerization domain, leucine rich repeat and ......
Chromosomal Location16p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CIITA. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CIITA.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCIITA
Nameclass II, major histocompatibility complex, transactivator
Aliases NLRA; NLR family, acid domain containing; nucleotide-binding oligomerization domain, leucine rich repeat and ......
Chromosomal Location16p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CIITA. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCIITA
Nameclass II, major histocompatibility complex, transactivator
Aliases NLRA; NLR family, acid domain containing; nucleotide-binding oligomerization domain, leucine rich repeat and ......
Chromosomal Location16p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CIITA expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCIITA
Nameclass II, major histocompatibility complex, transactivator
Aliases NLRA; NLR family, acid domain containing; nucleotide-binding oligomerization domain, leucine rich repeat and ......
Chromosomal Location16p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CIITA and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCIITA
Nameclass II, major histocompatibility complex, transactivator
Aliases NLRA; NLR family, acid domain containing; nucleotide-binding oligomerization domain, leucine rich repeat and ......
Chromosomal Location16p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CIITA collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.